1-Phenylpiperazine

9

Danger

H301 (96.9%): Toxic if swallowed [Danger Acute toxicity, oral]；H310 (36.9%): Fatal in contact with skin [Danger Acute toxicity, dermal]；H311 (61.5%): Toxic in contact with skin [Danger Acute toxicity, dermal]；H314 (98.5%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]

P260, P262, P264, P270, P280, P301+P316, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P354+P338, P316, P321, P330, P361+P364, P363, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 65 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.；Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.

Status: Active Update: 09-04-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/21606

Piperazine, 1-phenyl-, dihydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Phenylpiperazine: Does not have an individual approval but may be used under an appropriate group standard

Acute Tox. 3 (96.9%)；Acute Tox. 2 (36.9%)；Acute Tox. 3 (61.5%)；Skin Corr. 1B (98.5%)

Status: Active Update: 09-04-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/21606

Piperazine, 1-phenyl-, dihydrochloride: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Phenylpiperazine: Does not have an individual approval but may be used under an appropriate group standard

Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.

A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents).

Piperazine, 1-phenyl-: INACTIVE